1 m-Opioid receptors (mORs) are G-protein-coupled receptors that are activated by a structurally diverse spectrum of natural and synthetic agonists including endogenous endorphin peptides, morphine and methadone. The recent structures of the mOR in inactive 1 and agonist-induced active states (Huang et al., ref. 2) provide snapshots of the receptor at the beginning and end of a signalling event, but little is known about the dynamic sequence of events that span these two states. Here we use solution-state NMR to examine the process of mOR activation using a purified receptor (mouse sequence) preparation in an amphiphile membrane-like environment. We obtain spectra of the mOR in the absence of ligand, and in the presence of the high-affinity agonist BU72 alone, or with BU72 and a G protein mimetic nanobody. Our results show that conformational changes in transmembrane segments 5 and 6 (TM5 and TM6), which are required for the full engagement of a G protein, are almost completely dependent on the presence of both the agonist and the G protein mimetic nanobody, revealing a weak allosteric coupling between the agonist-binding pocket and the G-protein-coupling interface (TM5 and TM6), similar to that observed for the b2-adrenergic receptor 3 . Unexpectedly, in the presence of agonist alone, we find larger spectral changes involving intracellular loop 1 and helix 8 compared to changes in TM5 and TM6. These results suggest that one or both of these domains may play a role in the initial interaction with the G protein, and that TM5 and TM6 are only engaged later in the process of complex formation.
2) provide snapshots of the receptor at the beginning and end of a signalling event, but little is known about the dynamic sequence of events that span these two states. Here we use solution-state NMR to examine the process of mOR activation using a purified receptor (mouse sequence) preparation in an amphiphile membrane-like environment. We obtain spectra of the mOR in the absence of ligand, and in the presence of the high-affinity agonist BU72 alone, or with BU72 and a G protein mimetic nanobody. Our results show that conformational changes in transmembrane segments 5 and 6 (TM5 and TM6), which are required for the full engagement of a G protein, are almost completely dependent on the presence of both the agonist and the G protein mimetic nanobody, revealing a weak allosteric coupling between the agonist-binding pocket and the G-protein-coupling interface (TM5 and TM6), similar to that observed for the b2-adrenergic receptor 3 . Unexpectedly, in the presence of agonist alone, we find larger spectral changes involving intracellular loop 1 and helix 8 compared to changes in TM5 and TM6. These results suggest that one or both of these domains may play a role in the initial interaction with the G protein, and that TM5 and TM6 are only engaged later in the process of complex formation. The initial interactions between the G protein and intracellular loop 1 and/or helix 8 may be involved in G-protein coupling specificity, as has been suggested for other family A G-protein-coupled receptors.
mORs are membrane proteins belonging to the G-protein-coupled receptor (GPCR) superfamily that are responsible for the analgesic and addictive properties of morphine 4 , a natural alkaloid contained in opium 5 . In fact, due to the clinical importance of opioids in pain management and addiction, five decades of medicinal chemistry generated a very chemically diverse opioidergic ligand system (reviewed in ref. 6 ) that can modulate the mOR intracellular signalling, namely the inhibitory heterotrimeric G i protein and arrestin pathways 7 . The pharmacology of these different compounds are very well characterized and they present a wide spectrum of activity with respect to efficacy towards G protein and/or arrestin from very weak partial agonism to full agonism 7, 8 . Evidence suggests that activation of the arrestin pathway may be responsible for some of the adverse clinical effects of the opioids drugs currently on the market 7 .
Intrinsic efficacy is a parameter used to define the effect of a ligand on GPCR activation of specific signalling pathways 9 . To understand intrinsic efficacy, it is necessary to understand the process of GPCR activation. So far this process has only been described for three GPCRs using biophysical and crystallographic analyses of both inactive and active states: rhodopsin 10 , the b 2 -adrenergic receptor (b 2 AR) 11, 12 and muscarinic M2 receptor (M2R) 13 . The most complete characterization of the GPCR activation process by diffusible ligands came from NMR studies on the b 2 AR [14] [15] [16] [17] [18] , showing that the binding of agonist alone is associated with conformational heterogeneity in the receptor and is not sufficient to stabilize the active b 2 AR conformation. Whether this observation is generalizable to other GPCRs has not been determined.
Crystal structures are now available for the mOR in both inactive and fully agonist-induced states, representing the beginning and end of a signalling event (Huang et al., ref.
2). Here, in an effort to better understand the process of mOR activation upon binding of opioid agonists, we took advantage of the versatility of NMR spectroscopy (as recently described for the b 2 AR 19 ) to analyse the activation signal propagation occurring in different receptor domains (see Extended Data (Fig. 1a) that we unambiguously assigned to ten lysines and to the shortened N terminus (starting at G52) using systematic mutagenesis and proteolysis experiments (Extended Data Fig. 2 6.24 (ECL2, extracellular loop 2)) in the apo-state. Because a peak line width directly reports on the homogeneity of the local fluctuating magnetic field which depends on the dynamics of the labelled domain, this observation qualitatively indicates that the different domains under investigation (that is, TM6 and ICL1-helix 8 (H8)) present different dynamic properties (in the ms to ms range). Indeed, broad peaks suggest that the e-N[ 13 CH 3 ] 2 moieties detect two or more conformations (environments) that exchange on an intermediate time scale (low ms), while sharp peaks may represent a single conformation or two or more conformations that exchange on either a faster or slower time scale. The absence of a signal for a specific lysine may represent a lack of side chain dynamics or a dynamic timescale in the 'slow intermediate' regime 20 . We have focused our analysis on a specific set of NMR correlation peaks that were separated in two groups of sensors: the extracellular (G52 N-ter and K209
ECL2
) and intracellular (K98 ICL1 , K100 ICL1 , K260 5.66 , K269 6.24 , K271
6.26 and K344 8.51 ) lysines (Fig. 1b-d 4.43 ), and spectral modifications are difficult to interpret (Extended Data Fig. 2 ).
We first analysed the effect of BU72, a high-efficacy mOR agonist 21 , on the NMR signals using a saturating amount of ligand and/or a saturating amount of a G protein mimetic nanobody (Nb33) (Fig. 2) . We selected BU72 because of its extremely high efficacy/ potency and its slower dissociation rate relative to other agonists. Moreover, this ligand was successfully used in the crystallization studies (Huang et al., ref.
2). Nb33 is closely related to Nb39, the nanobody used to stabilize and capture the mOR agonist-induced state in crystallization studies (Huang et al., ref. 2). Nb33 and Nb39 differ by only two amino acids in a region that does not directly interact with the receptor, and they have similar G-protein-like effects on the affinity of agonist for the mOR. They also have similar effects in NMR experiments (Extended Data Fig. 3 ). We used Nb33 throughout this study because it can be purified in much larger quantities than Nb39 (see Methods).
In the extracellular surface, the peak corresponding to K209 ECL2 was slightly modified upon treatment with BU72 (Fig. 2a, LR panel) and, as better observed in the 1 H dimension, was decreased in intensity and shifted downfield (Fig. 2b, ECL2 panel) . As discussed above, this spectral modification indicates a change in the conformational state of the mOR, probably as a result of a modification of the K209 ECL2 microenvironment, as the b-hairpin containing this residue undergoes a change upon receptor activation (Fig. 1c) . When the sample was treated with a saturating concentration of the Nb33 only, no significant changes were observed (Fig. 2a, RNb panel) , suggesting an absence of environment changes around K209 ECL2 in the absence of agonist. When both BU72 and Nb33 were added to the 13 Cm2-mOR, the K209 ECL2 peak intensity decreased further as compared to the sample treated with BU72 alone (Fig. 2a , LRNb panel and Fig. 2b, ECL2 panel) . We also observed changes in the N terminus upon binding of BU72 alone; however, in this case the peak intensity increases. BU72 and Nb33 co-treatment slightly increased the effect observed for BU72 alone (Fig. 2b, N-terminal panel) . It is of interest that the active-state crystal structure of the mOR reveals that the N terminus folds into the binding pocket and interacts with BU72 (Huang et al., ref. 2) .
The potentiating effects of Nb33 on BU72 are much more pronounced in the intracellular part of 13 Cm2-mOR, as BU72 or Nb33 induced only small spectral changes by themselves (Fig. 2a , LR and RNb panels), while formation of the ternary complex led to more dramatic spectral modifications (Fig. 2a , LRNb panel). The proton peak centred around 2.9 p.p.m., which corresponds to the lysines K269 6.24 , K271
6.26 and K303 6.58 positioned in TM6, almost disappeared (the leftover peak being K303 6.58 , see assignments in Extended Data Fig. 2 ) with a concomitant appearance of an intense peak at 2.85 p.p.m. due to K269
6.24 and K271 6.26 alone (Fig. 2b , TM6 panel). This spectral shift, which is not observed in spectra from receptor treated with BU72 alone, is consistent with the 10 Å outward movement of TM6 upon receptor activation that repositions the K269 6.24 and K271 6.26 side chains (Fig. 1d) . The K260 5.66 peak intensity is also markedly decreased by exposure to both BU72 and Nb33, and thus represents a sensor for the receptor conformational change in TM5 (Fig. 2b, TM5 RESEARCH LETTER active conformations of TM5 and TM6 and support the notion of a weak connection between the ligand-binding and the G-protein-coupling domains of the mOR. This weak coupling was previously observed for the b 2 AR, and was thoroughly investigated more recently using NMR and DEER spectroscopy 3 . Of interest, the results obtained with the b 2 AR and the mOR stand in contrast to rhodopsin, for which a stronger link between photoisomerization of retinal and structural changes at the cytoplasmic end of TM6 has been observed 22 . In addition to the TM5 and TM6 probes, we also characterized the conformational transitions in the ICL1 (K98 ICL1 and K100
ICL1
) and H8 domains (K344 8.51 ) of mOR that also undergo conformational changes upon mOR activation (Fig. 1d) . Comparison of the R panel with the LRNb panel in Fig. 2a revealed a near complete loss of intensity of K98 ICL1 , K100
ICL1 and K344 8.51 peaks upon mOR treatment with BU72 and Nb33 (Fig. 2a, b , ICL1/H8 panels, green trace). While a complete loss of intensity for these peaks was only observed with both BU72 and Nb33, we did observe a reduction in intensity with BU72 alone (Fig. 2b, ICL1 /H8 panels, blue trace). The loss of peak intensity could originate from a change in the local dynamic of ICL1 and H8 domains in the ms to ms timescale that broadens the correlation peaks beyond the detection limit, a well characterized phenomenon in NMR spectroscopy 23 , and suggests that receptor activation is markedly modifying the structural dynamic of these domains. It should be noted that none of the lysines discussed here directly interact with the related Nb39 in the crystal structure. Changes in the NMR signal intensity therefore reflect the mOR activation process. Moreover, the effects of agonist and Nb33 can be reversed by treatment with the antagonist naloxone (Extended Data Fig. 4) .
Taken together our data demonstrate that binding of the G protein surrogate is required for the agonist to fully stabilize the active conformation in both extracellular and intracellular domains, suggesting the existence of a two-way allosteric coupling between the extracellular mOR ligand-binding domain and the G-protein-coupling interface. These data are in agreement with what has been observed with the isotopically labelled b 2 AR 14 , and suggest that this behaviour could be a common feature of the GPCR activation process.
We next quantitatively analysed the effect of BU72 alone (LR) and together with Nb33 (LRNb) on the volumes of the different intracellular lysine peaks (from TM5, TM6, ICL1 and H8 domains). Of particular interest, we found a notable difference in the effect of BU72 alone on TM5 and TM6 compared to its effect on ICL1 and H8 domains (Fig. 3a) . While BU72 alone had a slight effect on TM5 and TM6 signal intensity, it produced larger spectral changes for the ICL1 and H8 sensors (Fig. 3a) , suggesting that the allosteric coupling from the agonist-binding pocket to ICL1/H8 is stronger than the coupling to TM5 and TM6. This effect is not specific to BU72 as we observed the same phenomenon with two other agonists: [Dmt 1 ]DALDA (29,69-dimethyltyrosine-D-Arg-Phe-Lys-NH 2 ) and DAMGO (Tyr-D-AlaGly-NMe-Phe-Gly-ol) ( Fig. 3a and Extended Data Figs 5 and 6) . Notably, the formation of the ternary complex leads to larger volume changes for the different domains under investigation (Fig. 3b ) and, together with Fig. 3a , demonstrates that the fully agonist-induced state can only be achieved in the presence of an agonist and a G protein mimetic nanobody.
While we observe that agonists alone have larger effects on ICL1 and H8 reporters than on TM5 and TM6 reporters, our steady-state experiments do not provide information about the temporal sequence of these conformational changes; however, we speculate that a G protein may first engage ICL1 and/or H8 before engaging TM5 and TM6. In fact, the H8 domain is critical for G-protein coupling, as observed in rhodopsin 24 and for other GPCRs (see ref. 25 ). Notably, the H8 of the muscarinic M3R was shown to cross-link with the G aq protein in an agonist-dependent manner 26 , suggesting a close proximity between the receptor H8 domain and the G protein. Our results support a model where G protein could initially interact with the H8 and/or ICL1 domains of the receptor before docking in the 7TM core and stabilizing the TM5 and TM6 domains in an open conformation (Fig. 3c) .
Here we describe the measurement of conformational changes associated with mOR activation in both the extracellular and intracellular domains. Our data offer insights into agonist regulation of mOR subdomain conformations, revealing a possible allosteric pathway of activation from the agonist-binding pocket to the ICL1 and H8 domains to initiate the ternary complex formation and associated changes in TM5 and TM6. Importantly, our data complement the high-resolution structural data of the mOR agonist-induced state bound to BU72 described in a companion article (Huang et al., ref.
2) and offer unprecedented insights into the structural mechanisms of opioid receptor activation. A better understanding of the structural basis for opioid receptor activation may lead to new therapeutic approaches with fewer side effects.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Protein expression and purification. Nanobody (Nb) sequences were subcloned into a pMalp2x vector containing an N-terminal, 3C protease-cleavable maltose binding protein (MBP) tag and a C-terminal 8 3 His tag. Plasmids were transformed into BL21(DE3) cells and protein expression induced in lysogeny broth (LB) by addition of IPTG to 1 mM at an OD 600 of 0.8. After 24 h of incubation at 20 uC, cells were collected and sonicated in the presence of lysozyme and benzonase. MBP-nanobody fusions were purified by Ni-NTA chromatography and MBP was removed using 3C protease. Cleaved MBP was separated from the nanobody by additional amylose purification and size exclusion chromatography in a buffer containing 20 mM HEPES pH 7.5 and 0.1 M NaCl. Of note, because we needed large amounts of Nb for the NMR experiments, we decided to use Nb33 throughout this study as it was produced and purified in much larger quantities than Nb39 (almost ten times as much for the same volume of BL21(DE3) cell culture).
We generated a mOR mouse construct with features designed to enhance stability for NMR spectroscopy. A tobacco etch virus (TEV) protease recognition site was introduced after residue 51, and a human rhinovirus 3C protease site after residue 358. A Flag epitope tag was added to the amino terminus and an 8 3 His tag was appended to the carboxy terminus. Receptor expression was largely improved by using a M72T single-point mutation as assessed by naloxone binding. The final construct (mOR-2x) is shown in Extended Data Fig. 1 .
The mOR-2x construct was expressed in Sf9 cells using the Bestbac (Expression systems) baculovirus system in the presence of 3 mM naloxone. For all other mutants (assignments), we used the bac-to-bac system (Life Technologies). Sf9 cell cultures (Life Technologies) were grown to a density of 4 3 10 6 cells per ml, infected with baculovirus containing the mOR-2x genes, shaken at 27 uC for 48 h, and cell pellets were harvested and stored at 280 uC. The receptor was purified as previously described 1 and eluted from the anti-Flag M1 affinity resin with a buffer containing 0.01% MNG, 0.001% CHS, 20 mM HEPES pH 7.5, 0.1 M NaCl, 1 mM naloxone, 0.2 mg ml 21 Flag peptide and 2 mM EDTA. To remove flexible amino and carboxy termini, TEV and 3C protease were added at a 1:5 and 1:10 protease:mOR-2x ratio by weight. The sample was incubated at 4 uC overnight in the presence of 100 mM of TCEP. We then used a negative Ni-NTA chromatography step to remove TEV and 3C proteases. mOR reductive methylation. Receptor preparation from the Ni-NTA flow through were incubated at 4 uC overnight with 10 mM 13 C-formaldehyde and 10 mM NaBH 3 CN. Excess of reagent was eliminated by dialysis and 13 Cm2-mOR was further purified by SEC chromatography in a buffer containing 0.01% MNG, 0.001% CHS, 20 mM HEPES pH 7.5 and 0.1 M NaCl.
The monodisperse peak was then concentrated to 20 to 40 mM final, and dialysed in 98.85% D 2 O buffer with 0.01% MNG, 0.001% CHS, 20 mM HEPES-d18 pH 7.4 (uncorrected) and 40 mM NaCl. NMR spectroscopy. Final samples (,270 ml at 20-40 mM) were loaded into Shigemi microtubes susceptibility matched to D 2 O. All data for ligands and mutant studies were acquired on 700 MHz and 500 MHz Bruker Avance III spectrometers, respectively (Bruker, Rheinstetten, Germany), both equipped with 5 mm cryogenic H/C/N/D probes with z axis gradient. 1 H- 13 C correlation spectra were recorded using heteronuclear multiple-quantum coherence (HMQC) experiments in echo/anti-echo mode. 13 C and 1 H chemical shifts and peak line widths in the HMQC spectra reveal the chemical and magnetic environments of the 13 Cmethyl probes as well as their dynamic properties. Spectral widths in v1 and v2 were 8,417.5 Hz (6,009.6 Hz) and 3,519.6 Hz (2,515.2 Hz) at 700 MHz (500 MHz), respectively centred at 40 p.p.m. in the 13 C dimension. 13 C decoupling was performed with a GARP4 sequence. Typically, 134 (81) complex points with 32-48 scans per FID were recorded, to ensure a 27-Hz resolution per point at 700 MHz (500 MHz) before zero filling. The relaxation delay was set to 1.5 s. Thirty-two steady-state scans preceded data acquisition. Total collection time varied between 3 and 4 h, depending on the sample concentration. Spectra were processed using NMRPipe/NMRDraw software 27 and visualized using CCPNMR 28 . All ligands were dissolved in deuterated DMSO to 10 mM and directly added to the sample in the Shigemi tube at a final concentration of 150 mM. Nb33 and Nb39 were concentrated to 0.6 mM and dialysed in 100% D 2 O buffer with 0.01% MNG, 0.001% CHS, 20 mM HEPES-d18 pH 7.4 (uncorrected) and 40 mM NaCl. The nanobodies were added directly in the Shigemi tubes at a final concentration of 60 mM before data acquisition. Peak volume analysis. All NMR spectra were processed using the suite of programs provided in the NMRPipe/NMRDraw software distribution 27 . The spectra were normalized using DSS (2,2-dimethyl-2-silapentane-5-sulfonic acid) as an internal reference. For peak fitting analysis, spectra were processed with a squared sine-bell window function in each dimension, and zero-filled to 4096 3 1024 data points in time domain data t 2 and t 1 , respectively. Spectra were fit with the program nlinLS, provided as a part of nmrDraw package. Gaussian models were used for the fitting in each dimension, starting from values obtained from the peakpicking routine in nmrDraw. The quality of the fits was examined visually by estimating the residual difference between the experimental data and the results of the model calculations. Peak volumes in apo-state, ligands alone (BU72, [Dmt 1 ]DALDA, and DAMGO) and ternary complexes spectra were extracted from the peak fitting. Errors in the peak volume were calculated based on the effect of random noise for the peak height estimated by nlinLS.
To directly compare the ligand effects on the apo-state relative to the maximal effect obtained with BU72-Nb33 treatment (fully agonist-induced state), we normalized the peak volumes with the volume difference between the apo-state and ternary complex condition (BU72-Nb33) as the 100% (V apo 2 V BU72-Nb33 ). Ligand effects are represented as percentage of the maximal effect:
. For the TM6 data, because of the overlapping peaks in the area of interest, we considered the peak volume of K269 6.24 and K271 6.26 in the ternary complex with BU72 as the 100% (indicated as K269* and K271* in Cdimethylated mOR and quality control. The wild-type mOR contains a total of 12 lysine residues strategically positioned to sense conformational dynamics in both extracellular and G-protein-coupling domains upon receptor activation. To monitor the mOR activation process in solution in an amphiphile membrane-like environment, we exploit the sensitivity of two 13 C-methyl groups covalently bound to the e-NH 2 of lysine side chains (e-N[ 13 CH 3 ] 2 -lysines) and to the a-NH 2 of the receptor N terminus as NMR probes, an approach recently validated in the GPCR field 19 . We slightly modified the wild-type sequence to facilitate receptor purification and to remove flexible N and C termini for improvement of sample stability in NMR measurements. a, Snake plot presenting the mOR-2x construct and highlighting the 12 endogenous lysines (red circles), the protease cleavable motifs (black circles) and the Flag and 6 3 histidine tags (grey circle). Extracellular and intracellular surfaces are coloured yellow and blue, respectively. b, The different biochemical steps were analysed by SDS-PAGE (left panel) and a typical final size-exclusion chromatography highlighting the monodispersity of This reaction is known to minimally affect protein structure and function and, as previously observed with b2-AR (see ref. 19 ), it did not affect the functionality of mOR as 13 C-dimethylated mOR binds both antagonist (Naloxone) and agonist (BU72) with a similar affinity than unlabelled mOR Cdimethylated mOR using pull-down experiments (e), demonstrating that methylation does not prevent the agonist-dependent interaction with Nb39. Saturation binding experiments on soluble mOR or 13 C-dimethylated mOR (both at 100 nM) were done in the presence of an increasing amount of radiolabelled naloxone (up to 1 mM) and non-specific binding was determined in the presence of 100 mM of naloxone. Competition assays on soluble mOR or 13 C-dimethylated mOR were done with 100 nM of radiolabelled naloxone and increasing amount of BU72. Free and receptor-bound radioligands were separated using gel-filtration columns. Total binding was plotted as a function of [ Extended Data Figure 2 | Assignments of the N terminus and dimethyllysine peaks. Each single mutant was expressed, purified and labelled as described for mOR-2x. For each mutant, we analysed the R and LRNb spectra. a-k, Left panels represent the 2D spectra with the indicated lysine to arginine mutant in red. On the right panels, we highlight the peak disappearance for each mutant (red line) as compared to the wild-type mOR preparation (black line) in the 1 H dimension in the receptor alone condition (R). In some instances, peaks are overlapping in the area of interest and to assign these peaks we had to record the NMR spectra in the ternary complex situation (LRNb). This was the case for K269 (h), K271 (i), and K303 (j). In h, i and j, # indicates the position of the lysine peak from the Flag tag that we measured in some samples and that is due to an incomplete cleavage of the N terminus by the 3C protein. For samples used in the analysis of ligand and Nb effects, we almost eliminated this peak by optimizing the 3C cleavage step as described in the Methods (treatment with 100 mM TCEP). The peak denoted with a # in panel i between wild type (no TCEP) and K271R (100 mM TCEP) is an example of the improvement of 3C cleavage in TCEP-treated samples as indicated by the almost complete disappearance of the peak in both R and LRNb conditions (K271R, red line). The K98 peak was assigned by deduction (Fig. 1a) . Indeed, we generated and recorded NMR spectra of 11 mutants of the 12 endogenous lysines and the only peaks that were never affected in all the mutant spectra and left unassigned necessarily correspond to the K98 residue. l, The assignments of D1 (full-length N terminus) and G52 (cleaved N terminus) were inferred from the spectra obtained before (red line) and after cleavage with 3C (black line). The G52 loss of signal is better observed in the LRNb situation (G52* almost completely disappears). Asterisks indicate the chemical shifts of methyl probes in the ternary complex condition.
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Extended Data Figure 6 | Activation of mOR by DAMGO. a, HMQC spectra of unliganded 13 C-dimethylated mOR (30 mM, R, black), 13 C-dimethylated mOR treated with a saturating concentration of DAMGO (150 mM, LR, blue), 13 Cdimethylated mOR treated with DAMGO and a saturating concentration of Nb33 (60 mM, LRNb, green) and of unliganded RESEARCH LETTER
